Modulation of TIM receptor activity in combination with cytoreductive therapy

US9683049B2 · kind B2 · utility

Assignees

• The Board of Trustees of the Leland Stanford Junior University · US
• DANA-FARBER CANCER INSTITUTE, INC. · US
• Children's Medical Center Corporation · US

Inventors

• Jennifer Jones · Boca Raton, US
• Rosemarie Dekruyff · Newton, US
• Dale T. Umetsu · Stanford, US
• Gordon J. Freeman · Brookline, US
• Susan Knox · Stanford, US

Key dates

• Filing date: Apr 10, 2014
• Grant date: Jun 20, 2017
• Expiry date: Nov 10, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/75
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family is located within a region of human chromosome 5 that is commonly deleted in malignancies and myelodysplastic syndrome. Polymorphisms in the gene sequences are associated with the development of airway hyperreactivity and allergic inflammation, and T cell production of IL-4 and IL-13. The proteins include the human hepatitis A cellular receptor, hHAVcr-1.